| Name | Title | Contact Details |
|---|
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.
Gavis Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmaprint Inc is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RESTAT is a West Bend, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nutravail Technologies is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.